NIH launches large clinical trial for immune modulators as COVID-19 treatments

Hospital News

The National Institutes of Health today announced the start of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.

NIH said the ACTIV-1 Immune Modulators trial will seek to determine if modulating immune responses that trigger so-called cytokine storms can reduce the need for ventilators and shorten hospital stays and whether the trialed therapeutics are able to restore balance to an overactive immune system.

Products You May Like

Articles You May Like

Supply chain pains: How Geisinger, Sutter and Intermountain are prepping for flu season
CMS to delay start date for radiation oncology model, as urged by AHA
Analysis: COVID-19 Ranks as a Top 3 Leading Cause of Death in the U.S., Higher than in Almost All Other Peer Countries
COVID-19 has sparked more concerns about healthcare costs, insurance, TransUnion says
8 hospital megaprojects in the US

Leave a Reply

Your email address will not be published. Required fields are marked *